Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Epigenetic modification in liver fibrosis: Promising therapeutic direction with significant challenges ahead

Acta Pharmaceutica Sinica B(2023)10.1016/j.apsb.2023.10.023Source: DataRank Database

Epigenetic modification in liver fibrosis: Promising therapeutic direction with significant challenges ahead is a research paper published in Acta Pharmaceutica Sinica B (2023). On theSindex it has a DataRank of 0. It has been cited 49 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access49 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 5.39)OA: goldTopics (34)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Yajing Li ORCID,Qi Zheng ORCID,Mingning Ding,Huiping Zhou ORCID,Xiaojiaoyang Li ORCID

Live enrichment

PubMed:38486982 PMC:PMC10935124 OpenAlex:https://openalex.org/W4388346670

National Institutes of Health

Grant: R01 R01DK-057543

Fundamental Research Funds for the Central Universities

Grant: 2023-JYB-JBZD-046

BLRD VA

Grant: IK6 BX004477

BLRD VA

Grant: I01 BX005730

NIDDK NIH HHS

Grant: R56 DK115377

NIDDK NIH HHS

Grant: R01 DK057543

National Institutes of Health

Grant: 5I01BX005730-03

Bile Acids and Sphingosine 1-Phosphate in Non-Alcoholic Steatohepatitis (NASH)

National Institutes of Health

Grant: 5R01DK057543-02

BILE ACID SIGNALING &HEPATIC CHOLESTEROL METABOLISM

National Institutes of Health

Grant: 5IK6BX004477-02

BLR&D Research Career Scientist Award Application

FWCI

5.39

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.apsb.2023.10.023

publisherhttps://doi.org/10.1016/j.apsb.2023.10.023

publisherhttps://api.elsevier.com/content/article/PII:S2211383523004239?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2211383523004239?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38486982

Fields of Study

MicroRNA in disease regulationCancer-related gene regulationRNA modifications and cancer0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

EpigeneticsDruggabilityDNA methylationBioinformaticsHistoneFibrosisMedicineSteatohepatitisCancer researchLiver fibrosisMechanism (biology)Fatty liverBiologyPathologyDiseaseGeneticsDNAGeneGene expressionHistone acetylationnon-coding RNAhistone methylationDrug DevelopmentMrna MethylationEpigenetics RegulationTherapeutics. PharmacologyRM1-950Review

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being